

Entwicklung einer CRF-Bibliothek für OpenClinica auf Basis von CDISC CDASH

Henrik Dittmann

Institut Jules Bordet, Brüssel



Institut Jules Bordet

Das Institut Jules Bordet

- auf Onkologie spezialisiertes Krankenhaus
- Teil des Netzwerks der öffentlichen Krankenhäuser in Brüssel
- Teil der Université Libre de Bruxelles



Szenario für OpenClinica


- eCRFs für akademisch initiierte klinische Studien
- komplexe CRFs, kurze Laufzeiten, geringe Mittel
- Ansatz: Verwendung von OpenClinica in Verbindung mit CDISC CDASH
 - Standardisierung
 - Wiederverwendbarkeit
 - zügige Erstellung

Akademisch initiierte klinische Studien am Institut Jules Bordet

- Erwartung: ca. zehn Phase-II-Studien pro Jahr mit OpenClinica
- 20-200 Teilnehmer/innen, in der Regel in mehreren Zentren, teils in mehreren Ländern
- in OpenClinica 30-40 CRFs, verteilt auf 10-15 Study Events
- OpenClinica Enterprise Edition 3.1.3.1 seit Mai 2013
- Aktuell: eCRF für eine Studie in Verwendung, zwei sind im Test, zwei in der Entwurfsphase

Struktur und Ressourcen

- Clinical Trial Support Unit



- eCRFs werden derzeit auf Papier entworfen
- Erfahrung mit großen Phase-III-Studien im Datenzentrum BrEAST
- erstes eCRF maßgeblich implementiert durch Trial Data Solutions, Amsterdam

CDISC CDASH

- CDISC: Standardisierung von Daten und Metadaten in der klinischen Forschung (www.cdisc.org)
- Standards für Zulassungsanträge bei der FDA (SDTM, ADaM, SEND, SDTM-Terminologie)
- CDASH: Standard für die Datenerfassung, eng verbunden mit SDTM

Beispiel: CDASH

| | Question Text | Prompt | SDTM or CDASH Variable Name | BRIDG | Definition | CRF Completion Instructions | Information for Sponsors | Core |
|----|--|-----------------------------------|-----------------------------|---|--|---|--|------|
| 13 | Is this event related to study treatment? | Relationship to Study Treatment | AEREL | EvaluatedActivityRelationship.probabilityCode | Indication of whether the study treatment had a causal effect on the adverse event, as determined by the clinician/investigator. | Indicate if the cause of the adverse event is related to the study treatment and cannot be reasonably explained by other factors (e.g., subject's clinical state, concomitant therapy, and/or other interventions). | Sponsored-defined terminology will be used to indicate the relationship between the AE and the study treatment (e.g. ICH E2B examples: Not Related, Unlikely Related, Possibly Related, Related). *See the BRIDG model for | HR |
| 14 | What action was taken with study treatment? | Action Taken with Study Treatment | AEACN | DefinedActivity.name Code * | Changes made to the study treatment in response to the adverse event. {ACN} (See Section 2.2.) | Record changes made to the study treatment resulting from the adverse event. | CDISC controlled terminology should be used to indicate the action taken with the study treatment in response to the AE. *See the BRIDG model for complete path. | HR |
| 15 | What other action was taken in response to this adverse event? | Other Action taken | AEACNOTH | DefinedActivity.name Code * | Describes Other Action(s) taken in response to the adverse event that are unrelated to study treatment dose changes. | Record all other action(s) taken resulting from the adverse event that are unrelated to study treatment. | This field is usually collected as a free text field. Example: Treatment Unblinded, Primary Care Physician Notified. *See the BRIDG model for complete path. | O |
| 16 | What was the outcome of this adverse event? | Outcome | AEOUT | PerformedObservation.Result.value* | Description of the subject's status associated with an event. {OUT} (See Section 2.2.) | Record the appropriate outcome of the event in relation to the subject's status. | CDISC controlled terminology should be used to indicate the outcome of the event as it relates to the subject's status. The Outcome controlled terminology includes ICH E2B values. *See the BRIDG model for complete path. | HR |

Beispiel: Struktur einer Studie

| Title | Screening | Treatment | | | | Follow-up | | Common and unscheduled events | | | | | | |
|---------------------------|-----------|------------------|-----------------|---------|---------|---------------------------------------|--------------------|----------------------------------|-------------------------|---------------|-------------|-------------------|-------------|-------|
| | Screening | Cycle 1, Day 1/8 | Cycle 1, Day 14 | Cycle 2 | Cycle * | End of Treatment and Safety Follow-up | Survival Follow-up | Administration of the Study Drug | Concomitant Medications | Adverse Event | Unscheduled | Lab Normal Values | Progression | Death |
| | Scre | D1/8 | D14 | Cyc 2 | Cyc * | EoT/Sfty | Swvl * | Drug | ConMed | AE * | Unsched | LNV | PD | Death |
| Registration / IE Crit. | X | | | | | | | | | | | | | |
| Phys. Exam. / Vital Signs | X (v1) | X (v2) | X (v2) | X (v2) | X (v2) | X (v2) | | | | | | | | |
| Haematology | X | X | | X | X | X | | | | | | | | |
| Coagulation Profile | X | X | | X | | X | | | | | | | | |
| Liver Function Tests | X | X | | X | X | X | | | | | | | | |
| Blood Chemistry | X | X | | X | X | X | | | | | | | | |
| Electrolytes | X | X | | X | X | X | | | | | | | | |
| Thyroid Function Test | X | X | | X | | X | | | | | | | | |
| Urine Analysis | X | | | X | | X | | | | | | | | |
| Biological Samples | X (v1) | | X (v2) | | X (v2) | | | | | | | | X (v3) | |
| ¹⁸ F-DG PET/CT | X | | X | | | | | | | | | | | X |
| ECG | X | | | | X | | | | | | | | | |
| LVEF | X | | | | X | | | | | | | | | |
| Colorectal Cancer History | X | | | | | | | | | | | | | |
| Colorectal Cancer Surgery | X | | | | | | | | | | | | | |
| Prior Anti-Cancer Treatm. | X | | | | | | | | | | | | | |
| Prior Radiotherapy | X | | | | | | | | | | | | | |
| Medical History | X | | | | | | | | | | | | | |
| Imaging Examination | X | | | | X | X | | | | | | | | |
| Lesion Sites | X | | | | X | X | | | | | | | | |
| Tumour Response Eval. | X | | | | X | X | | | | | | | | |

und 11 weitere CRFs



Beispiel: eCRF-Definition


| | A | B | C | N | O | P | |
|----|-----------|---|---|---------------|----------------|--|---|
| 1 | ITEM_NAME | DESCRIPTION_LABEL | LEFT_ITEM_TEXT | RESPONSE_TYPE | RESPONSE_LABEL | RESPONSE_OPTIONS_TEXT | RESP |
| 2 | XPPERF | XPPERF: Whether radiation therapy was performed | Was radiation therapy performed before the subject entered the trial? | single-select | NY | , Yes, No | , Y, N |
| 3 | XPLOC | XPLOC: Specifies anatomical site of the radiation therapy | Anatomical Location | single-select | LOC | , Abdominal Cavity, Adrenal Gland, Bladder, Bone, Breast, Central Nervous System, Cervix Uteri, Chest, Colon, Colorectal, Esophagus, Head and Neck, Heart, Kidney, Liver, Lung, Lymph Node, Oral Cavity, Ovary, Pancreas, Pelvis, Peritoneum, Pleural Cavity, Prostate Gland, Rectum, Skin, Small Intestine, Spleen, Stomach, Testis, Thyroid Gland, Other, Whole Body | , ABDI BLADI NERV COLO HEAD LUNG OVAR PERIT PROS INTES THYR |
| 4 | XPLAT | XPLAT: Laterality of the anatomical site | Laterality | single-select | LAT | , Left, Right, Bilateral, Not Applicable | , LEFT |
| 5 | XPDOSTOT | XPDOSTOT: Total dose of radiation therapy | Total Dose | text | | | |
| 6 | XPDOSU | XPDOSU: The unit associated with the radiation therapy | Dose Unit | single-select | UNIT | , Gy, cGy, Rad | , Gy, c |
| 7 | XPSTDAT | XPSTDAT: Date when the therapy was first given | Start Date | text | | | |
| 8 | XPENDAT | XPENDAT: Date that the therapy was ended | End Date | text | | | |
| 9 | XPTRTSET | XPTRTSET: Setting of the radiation therapy | Setting | single-select | TRTSET | , Neoadjuvant, Adjuvant, Advanced | , NEO. |
| 10 | | | | | | | |





Beispiel: Terminologie


Title: Laboratory Analysis: Coagulation Profile



Instructions:










Page: Mark CRF Complete 


Lab panel 

Was the lab performed? *  If yes, please click on 'Save' and complete the extra questions and the table.

What was the ID of the laboratory used?  If the lab normal values are already recorded in a "Lab Normal Values" page, please reference this page (**by the occurrence number of the LNV study event**), otherwise complete a new "Lab Normal Values" page and reference that page here.

What was the lab specimen collection date?  

| Test | Result | Units | |
|--|--|--|----------------------------------|
| <input type="text" value="Activated Partial Thromboplastin Time"/>  | <input type="text"/>  | <input type="text" value="sec"/>  | <input type="button" value="X"/> |
| <input type="text" value="Prothrombin Time"/>  | <input type="text"/>  | <input type="text" value="sec"/>  | <input type="button" value="X"/> |
| <input type="text" value="Prothrombin Intl. Normalized Ratio"/>  | <input type="text"/>  | <input type="text" value="RATIO"/>  | <input type="button" value="X"/> |
| <input type="button" value="Add"/> | | | |

[Return to top](#) Mark CRF Complete 

Probleme: OpenClinica

- Item names müssen pro CRF eindeutig sein – eine Eindeutigkeit pro Item Group wäre für normalisierte Strukturen wünschenswert
- OIDs ändern sich bei der Übertragung in eine andere Studie, was Konvertierung der Regeldateien erfordert

Probleme: CDISC CDASH etc.

- SDTM-Terminologie erscheint teils ungeeignet zur Abbildung der im CRF erhobenen Daten (v.a., wenn die Codelisten nicht erweiterbar sind)
- Einzelne Terme aus der Terminologie sind nicht an die PIs vermittelbar
- bisher sind vor allem Domänen beschrieben, die allgemein benötigt werden, die Therapeutic Area Standards stehen noch aus

Therapeutic Area Standards



Quelle:

<http://www.cdisc.org/therapeutic>

Therapeutic Area Standards Under Development

| | Coordinating Organization(s) | Stage 0 | Stage 1 | Stage 2 | Stage 3a | Stage 3b | Stage 3c |
|-----------------------------|------------------------------|-----------------|------------------|-----------------------|-----------------|---------------|-------------|
| | Project Manager | Scoping & Input | Concept Modeling | Standards Development | Internal Review | Public Review | Publication |
| Alzheimer's V1.1 | CPATH/CDISC Jon Neville | Jan | Mar | Jun | Jul | Sep | Q313 |
| Asthma V1 | CDISC Rhonda Facile | Jan | Mar | Jun | Jul | Sep | Q413 |
| Cardiovascular Endpoints V1 | CDISC/DCRI Amy Palmer | Jun | Jul | Aug | | | Q114 |
| Multiple Sclerosis V1 | CPATH/CDISC Bess Leroy | May | Aug | Jul | | | Q114 |
| Diabetes V1 | TCB/CDISC Rachael Zirkle | Mar | Jun | Aug | Sep | | Q114 |
| QT Studies V1 | TCB/CDISC John Owen | Jul | Sep | | | | Q214 |
| Traumatic Brain Injury V1 | CDISC TBD | Sep | | | | | Q214 |
| Hepatitis C V1 | TBD | Sep | | | | | Q314 |
| Schizophrenia V1 | CDISC/DCRI Amy Palmer | Oct | | | | | Q314 |
| Oncology | TBD | Oct | | | | | |

Project Status: Stage ongoing Stage completed *Italics = Projected*



Status und Ausblick

- derzeit noch in einem frühen Stadium
- mittelfristig: Bereitstellung einer Bibliothek standardisierter CRF-Module
- langfristig: konfigurierbare CRF-Module auf Basis standardisierter Datenelemente
- weitere Interessen in diesem Zusammenhang:
 - Best Practices in der eCRF-Erstellung
 - Automatisierung der Regelgenerierung

Diskussion

Vielen Dank für Ihre Aufmerksamkeit!

www.bordet.be

www.br-e-a-s-t.org

henrik.dittmann@bordet.be